ENGINEERED ANTIBODIES WITH NEW WORLD PRIMATE FRAMEWORK REGIONS
The present invention provides an antibody or antigen-binding portion thereof having a variable region comprising at least two complementarity determining regions (CDRs) and at least three framework regions. The the framework regions are, or are derived from New World primate framework regions, and at least one of the CDRs is a non-New World primate CDR.
1 : An antibody or antigen-binding portion thereof having a variable region comprising at least two complementarity determining regions (CDRs) and at least three framework regions, wherein the framework regions are, or are derived from New World primate framework regions, and wherein at least one of the CDRs is a non-New World primate CDR.
2 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises three CDRs and four framework regions.
3 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises at least one murine CDR sequence.
4 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises at least one mouse CDR sequence.
5 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises at least one rat CDR sequence.
6 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises at least one human CDR sequence.
7 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises at least one synthetic CDR sequence.
8 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises at least one rabbit CDR sequence.
9 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises a combination of CDRs from differing sources.
10 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises 3 murine CDR sequences.
11 : An antibody or antigen-binding portion thereof according to claim 10 wherein the 3 murine CDR sequences are mouse CDR sequences.
12 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises 3 human CDR sequences.
13 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises 4 New World primate framework sequences.
14 : An antibody or antigen-binding portion thereof according to claim 1 wherein the variable region comprises 4 framework regions in which the framework regions are derived from New World primate framework regions.
15 : An antibody or an antigen-binding portion thereof according to claim 1 wherein the antigen-binding portion is a domain antibody.
16 : An antibody or an antigen-binding portion thereof according to claim 1 wherein the antibody or antigen-binding portion further comprises a human or non-human Old World primate constant region sequence.
17 : An antibody or antigen-binding portion thereof according to claim 1 wherein the New World primate framework regions are from a New World primate selected from the group consisting of marmosets, tamarins, squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey.
18 : An antibody or antigen-binding portion thereof according to claim 17 wherein the New World primate is a marmoset.
19 : An antibody or antigen-binding portion according to any claim 1 wherein the antibody or antigen-binding portion binds to an antigen that is peptide, protein, carbohydrate, glycoprotein, lipid or glycolipid in nature, selected from a tumour-associated antigen including carcinoembryonic antigen, EpCAM, Lewis-Y, Lewis-Y/b, PMSA, CD20, CD30, CD33, CD38, CD52, CD154, EGF-R, Her-2, TRAIL and VEGF receptors, an antigen involved in an immune or inflammatory disease or disorder including CD3, CD4, CD25, CD40, CD49d, MHC class I, MHC class II, GM-CSF, interferon-γ, IL-1, IL-12, IL-13, IL-23, TNF-α, and IgE, an antigen expressed on a host cell including glycoprotein IIb/IIIa, P-glycoprotein, purinergic receptors and adhesion receptors including CD11a, CD11b, CD11c, CD18, CD56, CD58, CD62 or CD144, an antigen comprising a cytokine, chemokine, growth factor or other soluble physiological modulator or a receptor thereof including eotaxin, IL-6, IL-8, TGF-β, C3a, C5a, VEGF, NGF and their receptors, an antigen involved in central nervous system diseases or disorders including β-amyloid and prions, an antigen of non-human origin such as microbial, nanobial or viral antigens or toxins including respiratory syncitial virus protein F, anthrax toxin, rattle snake venom and digoxin; wherein the chimeric antibody acts as an agonist or antagonist or is active to either deplete (kill or eliminate) undesired cells (eg. anti-CD4) by acting with complement, or killer cells (eg. NK cells) or is active as a cytotoxic agent or to cause Fc-receptor binding by a phagocyte or neutralizes biological activity of its target.
20 : An antibody or antigen-binding portion thereof according to claim 19 wherein the antigen is human TNFα.
21 : An antibody or antigen-binding portion thereof according to claim 1 wherein the sequence of at least one framework region is modified to increase binding.
22 : An antibody or antigen-binding portion thereof according to claim 1 wherein the sequence of at least one framework region is modified to decrease predicted immunogenicity in humans.
23 : A kit comprising an antibody or an antigen-binding portion thereof according to claim 1 , or a pharmaceutical composition thereof, packaging and instructions for use.
24 : A designed New World primate antibody or antigen-binding portion thereof which binds a cell surface antigen or a cytokine wherein the antibody or antigen-binding portion thereof comprises a variable region comprising at least two complementarity determining regions (CDRs) and at least three framework regions, wherein the CDRs are selected such that the antibody or antigen-binding portion binds to the cell surface antigen or to the cytokine.
25 : A designed New World primate antibody or antigen-binding portion thereof as claimed in claim 24 wherein the antibody or antigen-binding portion thereof binds to a cell surface antigen selected from the group consisting of CD3, CD20, CD33, EGF-R, Her-2 and CD25.
26 : A designed New World primate antibody or antigen-binding portion thereof as claimed in claim 24 wherein the antibody or antigen-binding portion thereof binds to TNFα or VEGF.
27 : A designed New World antibody or an antigen-binding portion thereof according to claim 24 wherein the antigen-binding portion is a domain antibody.
28 : A designed New World antibody or an antigen-binding portion thereof according to claim 24 wherein the antibody or antigen-binding portion further comprises a human or non-human Old World primate constant region sequence.
29 : A designed New World antibody or antigen-binding portion thereof according to claim 24 wherein the New World primate is selected from the group consisting of marmosets, tamarins, squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey.
30 : A designed New World antibody or antigen-binding portion thereof according to claim 29 wherein the New World primate is a marmoset.
31 : A designed New World antibody or antigen-binding portion thereof according to claim 24 wherein the sequence of at least one framework region is modified to increase binding.
32 : A designed New World antibody or antigen-binding portion thereof according to claim 24 wherein the sequence of at least one framework region is modified to decrease predicted immunogenicity in humans.
33 : A kit comprising a designed New World antibody or an antigen-binding portion thereof according to claim 24 , or a pharmaceutical composition thereof, packaging and instructions for use.